People: Synageva Biopharma Corp (GEVA.O)
40.29USD
22 May 2013
$0.77 (+1.95%)
$39.52
$39.58
$40.64
$39.17
123,513
100,416
$58.00
$34.01
Malley, Thomas
Brief Biography
Mr. Thomas R. Malley is Independent Director of Synageva Biopharma Corp. since November 2, 2011, and prior to that time served as a director of Private Synageva since October 2006. Since May 2007, Mr. Malley has served as President of Mossrock Capital, LLC, a private investment firm. From December 1998 to May 2007, Mr. Malley served with Janus Mutual Funds, including as Vice President and Portfolio Manager for the Janus Global Life Sciences Fund. From April 1991 to December 1998, Mr. Malley served as an equity analyst for Janus Mutual Funds. Mr. Malley previously served as a director of Cougar Biotechnology, Inc. from 2007 to 2009, which was a publicly traded company until Johnson & Johnson acquired the company in 2009. Mr. Malley is also a director of Puma Biotechnology, Inc., a publicly traded biotechnology company. Mr. Malley holds a B.S. in Biology from Stanford University.
Basic Compensation
| Total Annual Compensation, | Long-Term Incentive Plans, | All Other, | Fiscal Year Total, |
|---|---|---|---|
| -- | -- | -- | -- |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | -- | -- |
| Unexercisable | -- | -- |
| Excercised | -- | -- |
| Name | Fiscal Year Total |
|---|---|
Sanj Patel |
3,127,160 |
Carsten Boess |
1,091,660 |
Eric Grinstead |
-- |
Anthony Quinn |
1,263,770 |
Felix Baker |
-- |
Stephen Biggar |
-- |

